Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IZABRIGHT-Breast01
CTR20254230Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in triple-negative breast cancer (TNBC), breast cancer, sponsored by Biokin Pharmaceutical. Started Dec 2025; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on CTR20254230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254230.